



RxWIRE

A weekly service from
Pharmaceutical Strategies Group.

November 10, 2016

Creating opportunity for our clients with an exclusive focus on pharmacy solutions.

CVS expects to lose 40 million prescriptions to Walgreens

Boston Globe - November 8



CVS Health Inc. pared back its earnings outlook Tuesday after announcing it expected to lose 40 million retail prescriptions to its rival, Walgreens Boots Alliance.

[READ MORE](#)

SUMMARY OF TOP ARTICLES

'Every element' of Obamacare to be challenged after Trump victory

EBNews - November 9

After Donald Trump's surprising upset in the presidential race, the question for employers is: Just what will a President Trump mean for healthcare and employee benefits?

'Safety-net' hospitals ask for federal probe of possible EpiPen overcharges

CNBC - November 4

Will Mylan have to cut another very big check because of the way it's classified its EpiPen for sales to poor people?

U.S. Charges in Generic-Drug Probe to Be Filed by Year-End

Bloomberg - November 3



U.S. prosecutors are bearing down on generic pharmaceutical companies in a sweeping criminal investigation into suspected price collusion, a fresh challenge for an industry that's already reeling from public outrage over the spiraling costs of some medicines..

Specialty Pharmacy and Care Coordination: A Beneficial Relationship

Specialty Pharmacy Times - November 8

Care coordination has become the focus of many health care professionals and their respective organizations. By giving patients highly coordinated care, the expectation is that their health will improve.

How state-mandated formularies impact costs

Managed Healthcare Executive - November 12

State-mandated formulary provision experiences higher pharmacy costs and lower medication use, according to a poster presented recently at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting, October 3–6, in National Harbor, Maryland.

Under drug-cost attack, Big Pharma CEOs raise the value-based pricing flag

FiercePharma - November 7

Smart pharma CEOs are getting ahead of the drug pricing argument. Rather than getting in the trenches to defend their price tags, they're flanking the fight by talking up value-based payer deals.

What clinical trial results? Now you can see who isn't sharing their findings

STAT - November 3

The results for nearly half of all clinical trials conducted by big drug makers during the last decade have not been published, and one company — Ranbaxy Laboratories — has not published findings for any of the nearly three dozen trials conducted in the past 10 years, according to a new online tool.

Dealmakers Behind Soaring Drug Prices Hit the Jackpot

Bloomberg - November 2

Dealmakers have always flipped companies. Lately, they've been flipping something else: aging pharmaceuticals.

Fraud Cases Underscore New Challenges for Compounding Pharmacies

Specialty Pharmacy Times - November 3

Fraud is a leading concern of federal investigators and the compounding pharmacies they oversee.

Some Immune-Boosting Cancer Drugs May Pose Rare Heart Risks

Drug Discovery & Development - November 4

Doctors have found a disturbing downside to some powerful new drugs that harness the immune system to fight cancer: In rare cases, they may cause potentially fatal heart damage, especially when used together.

CVS Caremark earns URAC accreditations across several programs

Drug Store News - November 3

CVS Health announced Wednesday that pharmacy benefits manager CVS Caremark has earned URAC accreditations in Health Call Center for its Pharmacy Advisor counseling program as well as in Pharmacy Benefit Management and Drug Therapy Management.

NOW AVAILABLE!

Purchase your copy today

\$299

10% discount for PBMI members

P B Pharmacy Benefit Management Institute
M I

Health officials find first cases of new superbug in US

STAT - November 4

Just five months after federal health officials asked hospitals and physicians to be on the lookout for an often-fatal, antibiotic-resistant fungus called *Candida auris*, 13 cases have been reported, the Centers for Disease Control and Prevention announced Friday.

FDA NEWS

FDA Panel Narrowly Backs Cempra Antibiotic

Drug Discovery & Development - November 7

A panel of federal health advisers has narrowly recommended approval for an experimental antibiotic from Cempra Inc., a small North Carolina drugmaker.

Allergan's multidose Restasis nabs FDA approval, heads to battle with Shire's Xiidra

FiercePharma - November 1

It's not exactly going to be smooth sailing for Allergan's multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a new challenge named Xiidra lies ahead.



Copyright © 2016 Pharmaceutical Strategies Group LLC. All rights reserved.
www.psgconsults.com | 800.687.4404
2901 N. Dallas Pkwy. Suite #420 | Plano, TX 75093

ABOUT YOUR SUBSCRIPTION

You have received this email because you are signed up to receive RxWire from Pharmaceutical Strategies Group LLC. If you would like to stop receiving the RxWire newsletter, please [manage your preferences](#). If you know someone who would be excited to hear from us as well, [forward this email to your friend](#). If your email address has changed, please [update your account](#). Your privacy is our responsibility, and know that we do not rent, share or sell your email address or contact information with anyone. This email was sent to ckosha@nnebt.org.